While TMB-H predicted a response to ICI in those with a correlation between CD8 T-cells and neoadjuvant load (e.g., melanoma, bladder and lung cancer), this benefit was not seen in those tumor types where no such correlation was seen (e.g., breast, prostate, glioma). Here, CD8A is linked to neoplasm.